# Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

> **NCT01300234** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 512 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate (TDF) tablets
- **DRUG:** Adefovir dipivoxil (ADV) tablets

## Key facts

- **NCT ID:** NCT01300234
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-30
- **Primary completion:** 2012-10-17
- **Final completion:** 2016-12-06
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300234, "Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01300234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*